Baader Bank Aktiengesellschaft Invests $595,000 in iRadimed Corporation $IRMD

Baader Bank Aktiengesellschaft bought a new position in iRadimed Corporation (NASDAQ:IRMD) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 6,122 shares of the medical equipment provider’s stock, valued at approximately $595,000.

Several other large investors have also recently made changes to their positions in IRMD. CWM LLC increased its holdings in shares of iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 211 shares during the last quarter. Quarry LP bought a new stake in shares of iRadimed in the third quarter worth about $40,000. Farther Finance Advisors LLC increased its holdings in shares of iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 397 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in shares of iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 495 shares during the last quarter. Finally, State of Alaska Department of Revenue bought a new stake in shares of iRadimed in the third quarter worth about $47,000. 92.34% of the stock is owned by institutional investors.

Insider Activity

In other iRadimed news, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $101.38, for a total transaction of $506,900.00. Following the completion of the transaction, the chief executive officer owned 2,242,500 shares in the company, valued at $227,344,650. The trade was a 0.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders sold a total of 60,000 shares of company stock worth $5,661,603 in the last ninety days. 36.80% of the stock is owned by insiders.

Analyst Ratings Changes

Several research analysts recently commented on IRMD shares. Weiss Ratings upgraded iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 6th. Freedom Capital upgraded iRadimed to a “strong-buy” rating in a research report on Thursday, April 2nd. Lake Street Capital reiterated a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research report on Wednesday, February 11th. Finally, Roth Mkm reiterated a “buy” rating and issued a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $120.00.

iRadimed Trading Up 1.9%

IRMD opened at $86.89 on Friday. iRadimed Corporation has a 12 month low of $50.88 and a 12 month high of $107.90. The stock has a 50-day moving average of $94.05 and a 200 day moving average of $94.73. The firm has a market cap of $1.11 billion, a P/E ratio of 47.48 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The business had revenue of $21.98 million during the quarter, compared to analyst estimates of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, research analysts forecast that iRadimed Corporation will post 1.52 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be given a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th. iRadimed’s payout ratio is 43.72%.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.